For the Inventor, By the Inventor

Enter assignee name

San Mateo, CA, United States of America

Kronos Bio, Inc.

USPTO Granted Patents = 10

% Expired Patents = 10.0

CIPO Patents = 1

Forward Citations = 10

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Jeffrey E Kropf (4 out of 45 patents)

Aaron C Schmitt (4 out of 25 patents)

Seung H Lee (4 out of 37 patents)

4. Scott A Mitchell (4 out of 67 patents)

5. Zhongdong Zhao (4 out of 32 patents)

6. Peter A Blomgren (4 out of 53 patents)

7. Kevin S Currie (4 out of 72 patents)

8. Jianjun Xu (4 out of 40 patents)

9. Sundaramoorthi Swaminathan (3 out of 29 patents)

10. Jennifer R Lo (3 out of 18 patents)

11. Jin-Ming Xiong (3 out of 9 patents)

12. Henry G Morrison (2 out of 21 patents)

13. Peter Chee-Chu Fung (2 out of 4 patents)

14. Paul Robert Hartmeier (2 out of 2 patents)

15. Jesper Alexis Jernelius (2 out of 5 patents)

10 patents: Sort by Forward Citations

1. 12263163 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2025-04-01),

2. 12152037 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2024-11-26),

3. 12122781 - Hydrates of polymorphs of 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-a]pyrazin-8-amine bis-mesylate as Syk inhibitors (2024-10-22),

4. 11845754 - Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity (2023-12-19),

5. 11517570 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2022-12-06),

6. 11384082 - Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors (2022-07-12),

7. 11339168 - Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors (2022-05-24),

8. 11155560 - Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity (2021-10-26),

9. 10842803 - Imidazopyridines Syk inhibitors (2020-11-24),

10. 10828299 - Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2020-11-10),

Kronos Bio, Inc. is a biotechnology company developing therapies for cancer by targeting dysregulated transcriptional regulation. Using its proprietary platform, Kronos Bio is discovering and developing small molecule drugs to modulate transcriptional regulatory processes with the goal of improving outcomes for cancer patients.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

10 Patents

#78 in San Mateo, CA

#7,106 in California

#29,828 in US

#55,954 in the World

San Mateo, CA, United States of America

Kronos Bio, Inc.

Forward Citations = 10

30 inventors:

Jeffrey E Kropf (4 out of 45 patents)

Aaron C Schmitt (4 out of 25 patents)

Seung H Lee (4 out of 37 patents)

4. Scott A Mitchell (4 out of 67 patents)

5. Zhongdong Zhao (4 out of 32 patents)

Please report any incorrect information to [email protected]

Loading…